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Abstract
Background: Wnt signaling is activated in many types of cancer and normal physiological processes. Various Wnt-
related secreted factors may influence angiogenesis both in the tumor microenvironment and in normal tissues by
direct action on endothelial cells. The mechanism of this Wnt action in angiogenesis is not well defined. We
hypothesize that endothelial cells are responsive to Wnt signals and that Lef1, a member of the vertebrate-specific
Wnt/beta-catenin throughput-inducing transcription factors’ sub-family Lef1/Tcf1, mediates this responsiveness and
promotes endothelial cell invasion.
Methods: A human endothelial cell line, EAhy926 was exposed to Wnt3a or directly transfected with Lef1.
Readouts included assessment of nuclear beta-catenin, Wnt throughput with a SuperTOPflash reporter assay,
induction of Lef1 transcription, induction of matrix metalloproteinase (MMP)-2 transcription, cell proliferation and
cell invasion through a matrix in vitro. The effects on MMP2 were also evaluated in the presence of Lef1 silencing
siRNA.
Results: Wnt3a increased nuclear beta-catenin and up-regulated Wnt/beta-catenin throughput. Wnt3a increased
Lef1 transcription and activity of the Lef1 promoter. Both Wnt3a treatment and Lef1 overexpression induced MMP2
transcription but this effect was completely abrogated in the presence of Lef1 siRNA. Inhibition of Lef1 also
reduced basal MMP2 levels suggesting that Lef1 regulates MMP2 expression even in the absence of exogenous
Wnt pathway activation. Lef1 slightly increased proliferation of EAhy926 cells and increased invasion by more than
two-fold.
Conclusions: EAhy926 cells activate canonical Wnt signaling in response to Wnt3a ligand. The Wnt target Lef1
specifically regulates MMP2 expression in these cells and promotes endothelial cell invasion. The EAhy926 cell line
provides a convenient alternative to primary human umbilical vein endothelial cells (HUVEC) in the study of
angiogenesis and the role of Wnt signaling on endothelial cell function.
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Many types of cancer exhibit activated Wnt signaling
which contributes to tumor cell proliferation and inhi-
bits differentiation [1]. In addition, secretion of Wnt
ligands by malignant cells contributes to dynamic pro-
cesses in the tumor microenvironment. Wnt 2, Wnt3a,
Wnt 5b, and Wnt 16 expression is up-regulated in pros-
tate cancer [2]; Wnt2 and Wnt5a are over expressed in
colon cancer [3]. Down regulation of the Wnt inhibitory
protein sFRP3 in the stroma and activation of epithelial-
to-mesenchymal-transition, a process influenced by Wnt
signaling [4], is associated with a poor prognosis in
breast cancer [5].
In breast cancer, high endothelial marker content in
tumor surrounding stroma is also a predictor of poor
prognosis [5] and endothelial cells in the tumor micro-
environment may be influenced by Wnt signals. In squa-
mous cell carcinoma of the lung, intratumoral Wnt5a
gene expression correlates with tumor angiogenesis and
VEGF-A expression [6]. The Wnt pathway is a critical
mediator of endothelial function [7]. In the tumor
microenvironment, endothelial cells express multiple
components of Wnt signaling pathways such as Wnt
ligands, LRP5 [8], frizzled (Fz) receptors and soluble
Wnt inhibitors [9], [10], and can respond to exogenous
Wnt ligands [11]. The Wnt pathway is basally activated
in subconfluent endothelial cells [9] and may promote
endothelial cell proliferation. Wnt1 stabilizes active b-
catenin and promotes both proliferation and formation
of capillary-like networks in Matrigel [12], [10], an effect
that may be mediated through induction of interleukin
8, a known angiogenic factor which is a direct target
gene of Wnt/b-catenin signaling [13], [14] or hepatocyte
growth factor [15]. However, others [16] have suggested
that Wnt1 may have inhibitory activity on endothelial
cell proliferation. A different Wnt ligand, Wnt3a, has
been shown to induce endothelial cell proliferation and
migration in the context of DVL3 phosphorylation [17].
Endostatin inhibits endothelial cells by inducing G1
arrest. This effect is mediated by inhibition of cyclin D1
transcription. Cyclin D1 is regulated by Lef1, a member
of the Lef/Tcf transcriptional regulator family, which
mediates b-catenin dependent (i.e., canonical Wnt path-
way) transcription [18]. This suggests that the Wnt
pathway is a target for endostatin, and that inhibition of
Wnt signaling may be one mechanism by which endo-
statin is antiangiogenic. Soluble frizzled-related proteins,
inhibitors of Wnt signaling, also inhibit vascular
endothelial cell proliferation by delaying G1 and entry
into S-phase [19].
Vertebrate vascular system is closed and contains
more robustly streaming liquid compared with its analo-
gue in invertebrates such as Hydra or C. elegans.
Although Wnt pathway is involved in development of
the vertebrate vascular system, the mechanisms of this
involvement are largely unknown. Dietmar Gradl’sl a b
recently delineated Lef/Tcf factor’se v o l u t i o n .M a n y
invertebrates have only one Tcf factor from Tcf3/Tcf4
sub-family. For example, pop-1 (C. elegans’ Tcf) can
substitute Xenopus’ Tcf3; Hydra’sT c fc a ns u b s t i t u t e
Xenopus’ Tcf4 [20] and Dietmar Gradl’sp e r s o n a lc o m -
munication, 2011. Tcf1/Lef1 sub-family is present only
in vertebrates. Members of this sub-family generate
stronger Wnt throughput and Xenopus’ secondary axis
i n d u c t i o np e rp r o t e i nu n i tt h a nm e m b e r so fT c f 3 / T c f 4
sub-family [21]. Tcf1 is presented in adult mammalian
tissues mostly in its truncated dominant negative form
that lacks b-catenin binding domain and inhibits the
Wnt signaling [22] The higher activity of the only acti-
vating member from Lef1/Tcf1 subfamily in mammalian
tissues Lef1 could be at least partially explained by a
unique capacity of Lef1 to serve as a nuclear-b-catenin
retention factor [23]. Does formation of closed verte-
brate vascular system require this stronger signaling
from Lef1-representative of Tcf1/Lef1 sub-family? This
question is the focus of our work on human endothelial
cell line.
We hypothesized that endothelial cells would be
responsive to canonical Wnt signals and, since Lef1
increases the in vitro invasiveness of cancer cells [24],
[25], and this is in many ways a similar process to
endothelial cell migration through the basement mem-
brane, that these responses would be mediated by Lef1.
We show here that Wnt3a and Lef1 promote Wnt sig-
naling in and invasiveness of endothelial cells. The novel
information about the role of Lef1 in angiogenesis
improves our understanding as to how the Wnt pathway
regulates blood vessel growth both in normal physiologi-
cal conditions and in cancer.
Methods
Cell lines
The human endothelial-like immortalized cell line
EaHy926, derived from the fusion of human umbilical
vein endothelial cells (HUVEC) with the bronchial carci-
noma cell line A549, and expressing an endothelial-like
phenotype is a generous gift from Dr. CJ Edgell [26]. It
is grown in DMEM with 4.5g/l glucose and 10% FBS.
Parental L-cells and L-cells stably producing Wnt3a
were obtained from ATCC (ATCC#CRL-2647,
ATCC#CRL-2648).
Plasmid constructs & cell transfection
Expression plasmids utilized for transfection included a
b-catenin expression construct, a Lef1 expression con-
struct (FL9B), a Firefly luciferase reporter driven by the
Lef1 promoter (B5 in pGL2 vector) provided by Dr.
Marian Waterman (University of California, Irvine), and
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fornia). Plasmids for assay readouts included SuperTOP-
flash and as a control SuperFOPflash kindly provided by
Dr. Randall Moon (University of Washington), and
Renilla luciferase, pGL4.74 (Promega Corporation,
M a d i s o n ,W I ,C a t .# E 6 9 2 1 ) .T ransfection of plasmids
was performed using Lipofectamine 2000 (Invitrogen,
Cat. #11668-019) and Opti-MEM I Reduced Serum
Medium (Invitrogen, Cat. #11058-021), or BioT reagent
(Bioland Scientific, Cat. #B01-01) using the manufac-
turers’ protocols.
Treatment with Wnt ligands
Exposure to Wnt3a was accomplished utilizing two
methods: endothelial cells were co-cultured side-by-side
with Wnt3a producing L-cells [27] or they were treated
with Wnt3a conditioned media. Wnt3a conditioned
medium (CM) and control CM were prepared using
LWnt3A cell line (ATCC#CRL-2647), and the parental
cell line (ATCC #CRL-2648) according to procedures
perfected in the laboratory of Dr. Roel Nusse [28]; for a
preparation protocol, see http://www.stanford.edu/
group/nusselab/cgi-bin/wnt/. Cells were analyzed after
24 hours of Wnt3a treatment.
Evaluation of b-catenin by immunofluorescence staining
Cells were grown on Lab-Tek II chamber glass slides
(Nalge Nunc International). They were fixed with 4%
para-formaldehyde and treated 5 min at room tempera-
ture with 1% SDS in Tris-buffered saline for antigen
retrieval. Donkey serum was utilized as a blocking agent
to reduce background staining. Slides were incubated
with primary antibody for 60 minutes at 25°C. Anti-b-
catenin staining was performed with mouse monoclonal
antibodies obtained from Transduction Laboratories
(San Diego, clone C19220) or with anti-b-catenin rabbit
polyclonal antibodies (Sigma, St. Louis, MO, clone
C2206). Incubation with the primary antibody was fol-
lowed by incubation with biotinylated secondary anti-
body (final concentration 1µg/ml), and subsequently
with biotinylated horseradish peroxidase-avidin complex
(Santa Cruz biotechnology, Santa Cruz, CA). As a sub-
strate for peroxidase we used TSA Fluorescein System
(Tyramide Signal Amplification, PerkinElmer Life
Sciences, Cat. # NEL701A). Slides were visualized using
fluorescent confocal microscopy; not less than 100 cells
were analyzed with image quantification software to
determine the relative b-catenin fluorescence.
Wnt throughput assays
Firefly luciferase (SuperTOPflash or SuperFOPflash) and
Renilla luciferase, the latest utilized as a control for the
luciferase-based assays, were measured according to the
manufacturer’s instructions (Dual-Glo Luciferase Assay
System and Bright-Glo Luciferase Assay System, Pro-
mega, WI, USA).
Quantitative real-time PCR assays
The Lef1 mRNA levels were measured using cDNA
synthesis and quantitative real-time PCR (qRT-PCR).
RNA was purified with TRIzol reagent (Invitrogen). The
pellet was dissolved in 20µl of DEPC-treated water. 1µg
of the RNA was DNase treated, using Deoxyribonuclease
I, amplification grade (Invitrogen, catalog No. 18068-
015) according to the manufacturer’s procedure. qRT-
PCR was performed using One Step Applied Biosystems
Sybr Green kit (Cat. #4310179) under the following con-
ditions: reverse transcription reaction performed at 48ºC
for 30 min followed by heating at 95ºC for 10 min. The
PCR stage included 50 cycles of 15 sec dissociation at
95ºC and 1 min incubation at 60ºC. The identity of PCR
products was confirmed by analysis of dissociation
curves after the PCR. Actin was used for normalization.
Primers used for the full length Lef1 mRNA were: For-
ward - CCGAAGAGGAAGGCGATTTAGCT, Reverse -
GCTCCTGAGAGGTTTGTGCTTGTCT.
The MMP2 mRNA levels were measured by quantita-
tive real-time PCR (qRT-PCR) utilizing the same para-
meters described above for Lef1. Primer sequences were
[29]: Forward - CGCAGTGACGGAAAGATGTGGT,
Reverse - AGAGCTCCTGAATGCCCTTGATGT
Lef1 promoter activity
The B5 reporter construct, in which the LEF-1 promoter
drives Firefly luciferase, was utilized to evaluate Lef1
promoter activity. Renilla luciferase was utilized as a
control. Luciferase activity was measured using kits
from Promega, Dual-Glo Luciferase Assay System (Cat.
#E2920) and Bright-Glo Luciferase Assay System (Cat.
#E2610), according to the manufacturer’s instructions.
Proliferation assay
Cell proliferation was determined by MTT assay using a
Boehringer Mannheim Biochemica kit or by TACS
®
XTT Cell Proliferation Assay kit from R & D Systems,
(Cat. #4891-025-K) according to the manufacturer’s
recommendations. The cells were growing 96 - 120
hours.
Invasion assay
Invasion of the Matrigel™ (BD Biosciences, Cat. #
354234) was performed according to the manufacturer’s
procedure using BD control inserts (BD catalog No.
354578) filled with a diluted Matrigel matrix. The Matri-
gel concentration was optimized as described by Albini
[30]. 5 × 10
4 EAhy926 cells were plated over 3.3%
Matrigel for one insert in a 24-well culture plate. Con-
trol inserts not coated with Matrigel were used for
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72 hours after seeding.
Gene silencing
Small inhibitory RNA (siRNA) targeting Lef1 b-catenin
binding domain (CCCGAAGAGGAAGGCGATTTA
and AGGGCGATCCTCAGAAGGAAA), and control
random siRNA were obtained from Qiagen (Cat.
#1027415). Transfection with siRNA was performed
using BioT reagent (Bioland Scientific, Cat. # B01-01)
following the manufacturer’s protocol.
Statistical considerations
Comparison of expression and activity levels for the var-
ious assays examined were made with an unpaired t-
test, with the level of statistical significance defined as p
< 0.05.
Results and discussion
Wnt3a induces canonical Wnt signaling in endothelial
cells
Primary human umbilical vein endothelial cells
(HUVEC) respond to Wnt3a treatment [17]. To define
the responsiveness of the EAhy926 cell line to Wnt sig-
nals, these cells were exposed to Wnt3a by conditioned
media (CM) and also cultured in side-by-side co-culture
with Wnt3a producing L-cells. Wnt3a CM promoted
localization of b-catenin to the nucleus, a hallmark of
canonical Wnt pathway activation (Figures 1A-D). The
ratio of nuclear to cytoplasmic b-catenin increased sig-
nificantly (Figure 1E; p < 0.0001). The basal level of
Wnt signaling in EAhy926 cells, as measured by Super-
TOPflash reporter activity, is low. Exposure to Wnt3a
CM led to a significant 50% increase in Wnt pathway
throughput (Figure 1F; p < 0.01). Incubation of
EAhy926 in side-by-side co-culture with Wnt3a produ-
c i n gL - c e l l sr e s u l t e di na ne v e nm o r ed r a m a t i c2 . 5 - f o l d
increase in reporter activity (Figure 1G; p < 0.01).
SuperFOPflash reporter with mutated Lef/Tcf binding
site does not react to Wnt3a. These data demonstrate
existence of an intact canonical Wnt signaling pathway
in EAhy926 cells responsive to exogenous Wnt3a; it is
consistent with the response of HUVECs to exogenous
Wnt signals which has been described by others [31],
[32], [10], [17].
Wnt3a increases Lef1 expression in endothelial cells
Lef1 promoter activity in EAhy926 endothelial cells was
measured by the response of a Lef1 promoter-driven
reporter construct (B5) to Wnt3a in side-by-side co-cul-
ture with Wnt3a-producing L-cells. Lef1 promoter activ-
ity increased significantly when compared to co-culture
with non-Wnt3a-producing parental L-cells (Figure 2A;
p = 0.0178). Quantitative real time PCR, utilizing
primers to detect full length (activating) Lef1 was per-
formed on EAhy926 cells following exposure to Wnt3a.
Wnt3a CM increased Lef1 mRNA expression 4000%
(Figure 2B; p = 0.0379) though initial concentrations of
Lef1 mRNA in unstimulated cells were very low. Lef1
mRNA levels were increased in EAhy926 cells trans-
fected with b-catenin and responsiveness to Wnt3a was
maintained with a 5-fold increase in mRNA levels fol-
lowing exposure to Wnt3a CM (Figure 2C; p = 0.0086).
We define Lef1 to be a Wnt target gene in EAhy926
cells, since Wnt3a increases Lef1 message levels and
promotes transcription driven off the Lef1 promoter.
Lef1 is described as a canonical Wnt pathway target
gene in other cell lines [33], perhaps regulated by E-tail
containing Tcf transcription factors [34].
Both Wnt3a and Lef1 elevate MMP2 mRNA level in
endothelial cells
Matrix metalloproteinase (MMP)-1 expression does not
change in HUVECs following stimulation by Wnt3a [17]
though MMP2 has been shown to respond to Wnt/b-cate-
nin pathway stimulation in other cell models [29], [4].
MMP2 plays a key role in the invasion through extracellu-
lar matrix [31]. Exposure of EAhy926 cells to Wnt3a CM
significantly increased MMP2 expression approximately 5-
fold compared to control (Figure 3A; p = 0.019). Similarly,
direct transfection of EAhy926 cells with a Lef1 expression
construct resulted in a 5-fold increase in MMP2 mRNA
levels (Figure 3B; p < 0.001) compared to vector-only con-
trol transfection. Both Wnt3a and Lef1 promote expres-
sion of MMP2 in EAhy926 cells. MMP2 hydrolyzes type
IV collagen and other connective tissue substrates. During
angiogenesis, the basement membrane is degraded, often
by metalloproteinases, to facilitate invasion of endothelial
cells through the membrane [35]. In some cancers, the
level of MMP2 is increased; for example, in cases of
human multiple myeloma MMP2 of bone marrow plasma
cells is up-regulated [31]. MMP2 is a target of canonical
Wnt signaling in T-lymphocytes [29] and in prostate can-
cer cells [4].
siRNA-mediated inhibition of Lef1 reduces endothelial cell
MMP2 mRNA levels and abrogates Wnt3a-dependent
induction of MMP2 expression
Lef1 is one of a family of transcription factors which, in
association with b-catenin, regulate gene expression as a
terminal event in the Wnt signaling pathway. In order
to determine whether Lef1 specifically regulates MMP2
expression, Wnt3a CM-induced increases in MMP2
mRNA expression were evaluated under normal condi-
tions (control siRNA) and after the knockdown of Lef1
(siLef1). Cellular Lef1 mRNA levels were reduced by 60-
75% by two different Lef1 siRNAs (Figure 3C). The
amount of Lef1 mRNA is reduced in cells treated with
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without stimulation Lef1 mRNA is hardly detectable
(Additional file 1).
These siRNAs completely abrogated the Wnt3a CM-
induced increase in MMP2 expression (Figure 3D; p =
0.03). Additionally, Lef1 siRNAs reduced MMP2
mRNA below basal levels despite exposure to Wnt3a.
This implies that in EAhy926 both basal and Wnt-
augmented expression of MMP2 is dependent specifi-
cally upon Lef1 and that endogenous MMP-2 tran-
scription is tightly regulated by Lef1, even in the
absence of Wnt pathway activation. It seems that Lef1
specifically regulates MMP2 expression since transfec-
tion with a full-length Lef1 expression construct does
not affect significantly the amount of MMP1 mRNA
(Additional file 2).
A  B 
C  D 
F  G 
E 
Figure 1 Wnt pathway activation by extracellular Wnt3a as reflected in nuclear b-catenin content and level of Wnt throughput in
EAhy926 endothelial cells. (A) Control cells were not treated with Wnt. (B) Cell treatment with Wnt3a increased their cytoplasmic and nuclear
b-catenin content. Cells were analyzed by immunofluorescence with primary antibodies against b-catenin, biotinylated secondary antibody, and
subsequently TSA Fluorescein System. (C) A typical control cell with b-catenin staining (green fluorescence) and nuclear staining (blue
fluorescence, DAPI). (D) A typical Wnt3a-treated cell. After treatment of cells with Wnt3a conditioned media (CM) b-catenin staining co-localized
with nuclei. (E) Ratio of nuclear to cytoplasmic b-catenin in the EAhy926 cells. Wnt3A CM increased the nuclear/cytoplasmic ratio (**p < 0.0001).
(F) Wnt throughput was measured by the SuperTOPflash reporter construct in EAhy926 cells. Wnt3a CM increased Wnt throughput (**p =
0.0038). No activation of the same reporter with mutated Lef/Tcf binding site (SuperFOPflash) indicated specificity of the Wnt3a-dependent cell
response. (G) Wnt throughput as measured by the SuperTOPflash reporter construct in EAhy926 cells. Exposure to Wnt3a by side-by-side co-
culture also increased Wnt throughput (**p = 0.0034). The SuperFOPflash reporter was used to check specificity of the response.
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Page 5 of 10Figure 2 Wnt3a effect on Lef1 transcription in endothelial cells. (A) Lef1 promoter (B5) activity in EAhy926 cells. Exposure to Wnt3a in side-
by-side co-culture activates the Lef1 promoter (*p = 0.0178). (B) Lef1 mRNA levels by quantitative real-time polymerase chain reaction (qRT-PCR)
in EAhy926 cells. Wnt3a CM increases the amount of Lef1 mRNA (*p = 0.0379). (C) Lef1 mRNA levels by qRT-PCR in EAhy926 cells overexpressing
b-catenin. Wnt3a CM increases the amount of Lef1 mRNA in cells with already activated by b-catenin Wnt signaling (**p = 0.0086).
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Figure 3 Relationship between Wnt3a, Lef1, MMP2 mRNA, endothelial cell invasion, and proliferation. (A) MMP2 mRNA levels by qRT-
PCR in EAhy926 cells. Wnt3a CM increases the amount of MMP2 mRNA (*p = 0.0187). (B) MMP2 mRNA levels by qRT-PCR in EAhy926 cells.
Transfection with a full-length Lef1 expression construct increases the amount of MMP2 mRNA (***p = 0.0005). (C) Lef1 mRNA levels by qRT-PCR
in EAhy926 cells with control CM (column 1), following Wnt3a CM (columns 2, 3, 4) and in the presence of two different Lef1 siRNA (columns 3
and 4). The amount of Lef1 mRNA is reduced in cells treated with siRNA. (D) MMP2 mRNA levels by qRT-PCR in EAhy926 cells with control CM
(column 1), following Wnt3a CM (columns 2, 3, 4) and in the presence of two Lef1 siRNAs (columns 3 and 4). Lef1 siRNA decreases MMP2 mRNA
in EAhy926 cells from baseline and abrogates Wnt3a-mediated MMP2 induction (*p = 0.03). (E) Proliferation by MTT assay of EAhy926 cells.
Transfection with a full-length Lef1 expression construct slightly increases proliferation after 96 hours (***p < 0.0001). (F) Invasion through
Matrigel matrix by EAhy926 cells. Transfection with a full-length Lef1 expression construct significantly increases % invasion (**p = 0.0036).
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Wnt signals are proliferative for most cell types. In
EAhy926, transfection with Lef1 slightly increased cell
proliferation as measured by an MTT assay (Figure 3E;
p < 0.0001). Longer growth time confirms the result
(Additional file 3). More importantly, consistent with its
effect on MMP2 expression seen here and prior studies
in breast cancer models [24], Lef1 promoted EAhy926
cellular invasion through a Matrigel matrix, increasing
this 2.5-fold from 8.23 ± 0.17% to 20.27 ± 1.96% (Figure
3F; p = 0.0036). Our data supports the hypothesis that
Lef1 is an essential component of the regulation of pro-
liferation and invasion of EAHy926 endothelial cells.
Lef1 also directly affects invasion of EAhy926
endothelial cells through a matrix in vitro, likely, at least
in part, through its actions on MMP2. In vivo, this prop-
erty is analogous to endothelial cell migration through
the extracellular matrix. Anti-Lef1 therapy has been pos-
tulated to reduce invasion of cancer cells [24], [25]. Both
Lef1 and MMP2 might also be considered as potential
new targets for anti-angiogenic therapy.
While our data points to the role of canonical (b-cate-
nin) Wnt signaling in angiogenesis regulation, additional
evidence suggests that non-canonical pathways may also
play a role. Wnt5a, a Wnt ligand typically inhibitory for
canonical signal transduction, can promote endothelial
cell proliferation and survival via a non-canonical ERK
1/2 dependent process [36]. The non-canonical planar
cell polarity component DAAM1 has also been impli-
cated [37]. Even traditional canonical Wnt ligands such
as Wnt3a may also affect endothelial cell function via
non-canonical processes involving Cam Kinase II [17].
Further research defining the roles and interactions of
canonical and non-canonical Wnt signaling pathways
will improve our understanding of the complex regula-
tion of endothelial cells.
Since Lef1-dependent Wnt throughput is stronger per
protein unit than Tcf4-dependent signaling prevalent for
example in a normal mammalian gut, we might need to
develop Lef1-specific inhibitors for the angiogenesis
control [38].
Our studies were performed in an immortalized cell
line derived from endothelial cells, and thus may not be
completely analogous to in vivo conditions. However,
when we compare our data concerning the endothelial
cell line EAhy926 with the results obtained by others
from study of primary HUVECs [17], it is apparent that
these two cell systems have many similarities (Table 1).
At least for the study of Wnt/b-catenin signaling and its
role in angiogenesis, EAhy926 is a readily available alter-
native to HUVECs.
Conclusions
In conclusion, our data, and recent findings of others,
demonstrate that canonical (b-catenin) Wnt signaling is
important for endothelial cell function in angiogenesis.
We additionally define Lef1 as the key downstream
effector for this pathway in endothelial cells through
regulation of MMP2 expression and cell invasion.
Additional material
Additional file 1: Effect of Lef1 siRNA on Lef1 mRNA in the absence
of Wnt3a. Full length Lef1 mRNA levels by qRT-PCR in EAhy926 cells
treated by control CM (without Wnt3a) in the presence of control RNA
(column 1) and Lef1 siRNA (columns 3 and 4). The amount of Lef1
mRNA is reduced in cells treated with siRNA even without stimulation by
Wnt3a (**p = 0.0018).
Additional file 2: Effect of Lef1 expression on MMP1 mRNA. MMP1
mRNA levels measured by qRT-PCR in EAhy926 cells. Transfection with a
full-length Lef1 expression construct does not affect significantly the
amount of MMP1 mRNA.
Additional file 3: Prolonged proliferation of EAhy926 cells
measured by XTT assay. Transfection with a full-length Lef1 expression
construct slightly increases proliferation of EAhy926 cells after 120 hours
(**p = 0.0077). Here we used the TACS
®® XTT Cell Proliferation Assay
from R & D Systems.
List of abbreviations
Fz : frizzled receptor; HUVEC : human umbilical vein endothelial cells; Lef1 :
Lymphoid enhancer-binding factor 1; LRP5 : low-density lipoprotein
receptor-related protein 5; MMP2 : metalloproteinase-2; Tcf1 : T-cell factor 1;
TSA : Tyramide Signal Amplification.
Table 1 Comparison Wnt-mediated regulation of the EAhy926 immortalized cell line and HUVECs.
Human endothelial immortalized cell line EAhy926, treated with Wnt3a (our results) Primary HUVECs, treated with Wnt3a [17]
Increase of nuclear b-catenin Stabilization of total cellular b-catenin
Activation of Wnt/b-catenin throughput Induction of DVL3 phosphorylation
Up-regulation of full length Lef1 Data are not available
Increase in proliferation (MTT) after Lef1 transfection Increase in proliferation (BrdU incorporation)
Elevation of MMP2 No change in MMP-1
Lef1 siRNA induced inhibition of MMP2 response Data are not available
Increase of invasion Increase of migration
Data are not available No effect on survival
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